# Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

> **NCT00847379** · PHASE2 · TERMINATED · sponsor: **PTC Therapeutics** · enrollment: 173 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy
- Becker Muscular Dystrophy

## Interventions

- **DRUG:** Ataluren

## Key facts

- **NCT ID:** NCT00847379
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01-31
- **Primary completion:** 2010-05-24
- **Final completion:** 2010-05-24
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2020-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00847379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00847379, "Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00847379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*